ClinicalTrials.gg
CompletedNCT00574795Updated Aug 8, 2012Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants

A Phase 3 interventional study of 13vPnC in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 24 sites in Japan. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-08.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Non-randomized
Ages
2 Months to 6 Months
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.

02

Conditions studied

  • Vaccines, Pneumococcal Conjugate Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2 to 6 month-old infant
  • Available for entire study period

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal vaccine.
  • Previous anaphylactic reaction to any vaccine or vaccine-related component.
  • to vaccination with a pneumococcal conjugate vaccine.
  • Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
  • Known or suspected immune deficiency or suppression.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
193 participants (actual)

Interventions

  • Biological13vPnC

    "First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series

    Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after 3-dose infant series (at 7 months of age)

Secondary outcomes

  1. Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series

    GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one mone month after 3-dose infant series (at 7 months of age)

  2. Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose

    Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after the toddler dose (at 12 - 15 months of age)

  3. Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose

    GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after the toddler dose (at 12-15 months of age)

Other outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after each dose

  2. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after each dose

07

Results

Posted Aug 8, 2012

Participant flow

Participants were recruited in Japan from September 2007 to February 2008.

Infant Series
Participant flow — Infant Series
Milestone13vPnC
Started193
Vaccinated dose 1193
Vaccinated dose 2190
Vaccinated dose 3190
Completed188
Not completed5
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation2
Withdrew: Adverse event1
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC
Started188
Completed185
Not completed3
Withdrew: Withdrawal by subject1
Withdrew: Adverse event2
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC
Started185
Completed184
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series

Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after 3-dose infant series (at 7 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series
percentage of participants13vPnC After Infant Series
Common Serotypes - Serotype 4100.0 (97.9 to 100.0)
Common Serotypes - Serotype 6B98.3 (95.1 to 99.6)
Common Serotypes - Serotype 9V100.0 (97.9 to 100.0)
Common Serotypes - Serotype 14100.0 (97.9 to 100.0)
Common Serotypes - Serotype 18C100.0 (97.9 to 100.0)
Common Serotypes - Serotype 19F97.2 (93.5 to 99.1)
Common Serotypes - Serotype 23F97.7 (94.3 to 99.4)
Additional Serotypes - Serotype 1100.0 (97.9 to 100.0)
Additional Serotypes - Serotype 3100.0 (97.9 to 100.0)
Additional Serotypes - Serotype 5100.0 (97.9 to 100.0)
Additional Serotypes - Serotype 6A100.0 (97.9 to 100.0)
Additional Serotypes - Serotype 7F100.0 (97.9 to 100.0)
Additional Serotypes - Serotype 19A100.0 (97.9 to 100.0)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Dose 113vPnC Dose 213vPnC Dose 313vPnC Toddler Dose
Tenderness - Any (n=165,156,147,143)13.319.914.318.2
Tenderness - Significant (n=160,152,143,132)0.60.00.00.0
Swelling - Any (n=176,173,165,163)47.253.853.957.1
Swelling - Mild (n=174,171,163,154)46.049.150.344.2
Swelling - Moderate (n=167,164,150,151)14.428.729.336.4
Swelling - Severe (n=160,153,143,132)0.01.30.72.3
Redness - Any (n=186,180,171,166)74.274.467.868.1
Redness - Mild (n=183,179,162,156)68.364.855.653.8
Redness - Moderate (n=170,168,157,155)24.743.538.940.6
Redness - Severe (n=160,153,143,132)0.01.30.71.5
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events
percentage of participants13vPnC Dose 113vPnC Dose 213vPnC Dose 313vPnC Toddler Dose
Fever ≥37.5°C (n=170,163,154,150)32.933.140.350.7
Fever ≥38°C but ≤39°C (n=163,156,146,137)6.712.210.320.4
Fever >39°C but ≤40°C (n=161,153,143,133)1.22.62.85.3
Fever >40°C (n=160,152,143,132)0.00.70.00.0
Decreased appetite (n=163,158,144,138)11.716.59.718.1
Irritability (n=170,166,149,140)30.636.123.526.4
Increased sleep (n=175,160,153,139)40.629.422.224.5
Decreased sleep (n=169,160,145,138)21.323.115.912.3
Hives (n=160,152,143,132)1.31.30.70.0
Medication to treat symptoms (n=160,153,145,135)1.96.55.58.1
Medication to prevent symptoms (n=160,153,144,134)0.63.32.13.0
SecondaryGeometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series

GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one mone month after 3-dose infant series (at 7 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series
μg/mL13vPnC After Infant Series
Common Serotypes - Serotype 46.76 (6.02 to 7.59)
Common Serotypes - Serotype 6B4.77 (4.07 to 5.59)
Common Serotypes - Serotype 9V3.39 (3.03 to 3.78)
Common Serotypes - Serotype 1414.69 (13.26 to 16.26)
Common Serotypes - Serotype 18C3.68 (3.27 to 4.14)
Common Serotypes - Serotype 19F5.71 (4.90 to 6.65)
Common Serotypes - Serotype 23F2.57 (2.21 to 3.00)
Additional Serotypes - Serotype 15.11 (4.48 to 5.82)
Additional Serotypes - Serotype 32.87 (2.55 to 3.24)
Additional Serotypes - Serotype 53.85 (3.42 to 4.33)
Additional Serotypes - Serotype 6A3.77 (3.35 to 4.25)
Additional Serotypes - Serotype 7F5.78 (5.19 to 6.45)
Additional Serotypes - Serotype 19A6.97 (6.25 to 7.77)
SecondaryPercentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose

Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after the toddler dose (at 12 - 15 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose
percentage of participants13vPnC After Toddler Dose
Common Serotypes - Serotype 4100 (97.9 to 100)
Common Serotypes - Serotype 6B100 (97.9 to 100)
Common Serotypes - Serotype 9V100 (97.9 to 100)
Common Serotypes - Serotype 14100 (97.9 to 100)
Common Serotypes - Serotype 18C100 (97.9 to 100)
Common Serotypes - Serotype 19F98.9 (96 to 99.9)
Common Serotypes - Serotype 23F98.9 (96 to 99.9)
Additional Serotypes - Serotype 1100 (97.9 to 100)
Additional Serotypes - Serotype 399.4 (96.9 to 100)
Additional Serotypes - Serotype 5100 (97.9 to 100)
Additional Serotypes - Serotype 6A100 (97.9 to 100)
Additional Serotypes - Serotype 7F100 (97.9 to 100)
Additional Serotypes - Serotype 19A100 (97.9 to 100)
SecondaryGeometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose

GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after the toddler dose (at 12-15 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose
μg/mL13vPnC After Toddler Dose
Common Serotypes - Serotype 49.70 (8.43 to 11.17)
Common Serotypes - Serotype 6B14.61 (12.52 to 17.05)
Common Serotypes - Serotype 9V4.49 (4.00 to 5.06)
Common Serotypes - Serotype 1416.33 (14.49 to 18.41)
Common Serotypes - Serotype 18C6.09 (5.34 to 6.95)
Common Serotypes - Serotype 19F12.20 (10.37 to 14.35)
Common Serotypes - Serotype 23F6.55 (5.53 to 7.75)
Additional Serotypes - Serotype 19.85 (8.62 to 11.27)
Additional Serotypes - Serotype 32.06 (1.83 to 2.32)
Additional Serotypes - Serotype 57.31 (6.52 to 8.20)
Additional Serotypes - Serotype 6A11.03 (9.69 to 12.55)
Additional Serotypes - Serotype 7F8.31 (7.39 to 9.35)
Additional Serotypes - Serotype 19A15.97 (14.07 to 18.13)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—9/193 (4.7%)192/193 (99.5%)
13vPnC Post-Infant Series—14/193 (7.3%)19/193 (9.8%)
13vPnC Toddler Dose—1/185 (0.5%)171/185 (92.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
Event13vPnC Infant Series13vPnC Post-Infant Series13vPnC Toddler Dose
BronchiolitisInfections and infestations2/1930/1930/185
Febrile convulsionNervous system disorders0/1932/1930/185
PertussisInfections and infestations0/1932/1930/185
PneumoniaInfections and infestations0/1932/1930/185
Pneumonia respiratory syncytial viralInfections and infestations2/1931/1930/185
AsthmaRespiratory, thoracic and mediastinal disorders0/1931/1931/185
Adenovirus infectionInfections and infestations1/1930/1930/185
BronchitisInfections and infestations0/1931/1930/185
Cellulitis staphylococcalInfections and infestations1/1930/1930/185
Enteritis infectiousInfections and infestations0/1931/1930/185
Most frequent other events
Showing 10 of 192
Most frequent other events
Event13vPnC Infant Series13vPnC Post-Infant Series13vPnC Toddler Dose
Injection site erythemaGeneral disorders163/1930/193115/185
Erythema (Any)Skin and subcutaneous tissue disorders134/1800/1930/185
Erythema (Any)Skin and subcutaneous tissue disorders138/1860/193113/166
Erythema (Mild)Skin and subcutaneous tissue disorders125/1830/19384/156
Erythema (Any)Skin and subcutaneous tissue disorders116/1710/1930/185
Erythema (Mild)Skin and subcutaneous tissue disorders116/1790/1930/185
Injection site swellingGeneral disorders121/1930/19394/185
Induration (Any)Skin and subcutaneous tissue disorders83/1760/19393/163
PyrexiaGeneral disorders108/1930/19380/185
Erythema (Mild)Skin and subcutaneous tissue disorders90/1620/1930/185

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC
Mean3.7 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC
Female93
Male100
08

Study locations

24 sites
  • Nagoya-shi, Aichi 466-8650, Japan
  • Toyohashi-shi, Aichi 441-8570, Japan
  • Chiba-shi, Chiba 261-0012, Japan
  • Matsuyama-shi, Ehime 790-8524, Japan
  • Fukuoka-shi, Fukuoka 811-1394, Japan
  • Fukuoka-shi, Fukuoka 813-0036, Japan
  • Fukuoka-shi, Fukuoka 814-0162, Japan
  • Fukuoka-shi, Fukuoka 819-0002, Japan
  • Maebaru-shi, Fukuoka 819-1138, Japan
  • Asahikawa-shi, Hokkaido 078-8211, Japan
  • Sapporo-shi, Hokkaido 006-0831, Japan
  • Sapporo-shi, Hokkaido 062-0931, Japan
  • Sapporo-shi, Hokkaido 063-0831, Japan
  • Yokohama-shi, Kanagawa 240-8555, Japan
  • Yokosuka-shi, Kanagawa 238-8558, Japan
  • Nangoku-shi, Kochi 783-8505, Japan
  • Ise-shi, Mie 516-0805, Japan
  • Tsu-shi, Mie 514-025, Japan
  • Yokkaichi-shi, Mie 510-8561, Japan
  • Kurashiki-shi, Okayama 701-0192, Japan
  • Meguro-ku, Tokyo 152-8902, Japan
  • Setagaya-ku, Tokyo 154-0002, Japan
  • Setagaya-ku, Tokyo 154-0017, Japan
  • Setagaya-ku, Tokyo 157-8535, Japan
09

References and documents

Publications

  • Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber WC, Scott DA; 3003 Study Group. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Pediatr Infect Dis J. 2013 Sep;32(9):984-9. doi: 10.1097/INF.0b013e318293007e. PubMed 23538524 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2007
First posted
Dec 17, 2007
Start
Sep 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Aug 8, 2012
Last update
Aug 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00574795
Responsible party
Sponsor
First posted
Dec 17, 2007
Start date
Sep 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Aug 8, 2012
Last update
Aug 8, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion